European medicines agency – – healthcare professionals

On this page, you will find information on the Agency’s activities that are most relevant to healthcare professionals, including news, and events.

You can contribute to the Agency’s work by responding to public consultations.

Learn more about how Healthcare Professionals are actively involved in the work of the Agency.


EMA has released an overview of its key recommendations in 2016 on the authorisation of new medicines. Health insurance cheap EMA recommended 81 medicines for marketing authorisation. Primary health care trenton ga This includes recommendations for 27 new active substances.

The revised framework describes the objectives of the Agency’s interaction with healthcare professionals. Home health care certification It aims to promote participation in EMA’s work and ensure a sustainable model of interaction with healthcare professionals. Cheap health insurance for international students The revised framework incorporates experience gained and aligns with the EU Network strategy to 2020. Health insurance license It complements the objectives of the frameworks of interaction with patients and consumers, and industry stakeholders.

In collaboration with the European Commission, EMA held a workshop on adaptive pathways to gather the views and proposals from stakeholders on the adaptive pathways approach, following the publication of the final report on the pilot project. Women’s health obgyn 18 representatives of patient, consumer and healthcare professional organisations participated in the workshop, which included a session on patients’ needs. Health insurance florida A summary report of the meeting is available.

Rapid developments in technology have led to the generation of vast volumes of data, which can potentially transform the way the benefit-risk of medicinal products is assessed. Health insurance michigan EMA held a workshop in November 2016 to gather information on the latest developments in big data from the perspective of all stakeholders. Uk women’s health This helps EMA and the European medicines regulatory network to identity how and when the multitude of data sources may contribute to medicine development, authorisation and post-marketing surveillance.

Workshop on revising the guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicines

The European Medicines Agency (EMA) held a public consultation a concept paper which outlined the major areas for revision of the ‘Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products’, from July to September 2016. Home health care insurance Subsequently, EMA published a draft revised guideline for public consultation, from November 2016 to February 2017. Women’s health group columbia tn This technical workshop aims to finalise the guidance with further involvement of stakeholders including from other regulatory agencies, pharmaceutical industry, contract research organisations and academia. Pillars of primary health care The focus of the workshop will be on discussing comments received during the public consultations, therefore participation of external stakeholders is limited to those individuals and organisations who submitted comments. Women’s health and surgery center The output of the workshop will be reflected in the final revised guideline and the published overview of comments.

Patients’ and Consumers’ Working Party (PCWP) and Healthcare Professionals’ Working Party (HCPWP) joint workshop on personalised medicines

The joint PCWP/HCPWP workshop on personalised medicines aims to create awareness among patient, consumer and healthcare professional organisations of how the work of the European Medicines Agency (EMA) relates to this topic. Prime care health The working parties will also reflect on priority areas for future contributions in broader multi-stakeholder discussions. Cheap medical insurance dubai The objectives of the workshop include understanding how European and global landscapes are shaping policy developments, illustrating how activities of the European medicines regulatory network contribute to personalised medicine with existing legislation and regulatory tools, discussing how clinical practice and public participation can support personalised medicine in the context of European Union (EU) regulatory activities and identifying areas requiring attention from EU regulators, patients, healthcare professionals and civil society at large. Private health insurance uk EMA will publish the presentations, video recording and a workshop report.

EMA Human Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting with all eligible organisations

This final meeting for 2016 brings together members of the Patients’ and Consumers’ Organisations’ Working Party (PCWP) and all eligible patient and consumer organisations. Women’s health norfolk ne Discussions will include the next steps for public engagement looking towards 2020; public hearings; PCWP topic group updates; and patient interaction with consumers. Women’s health study EU-wide initiatives to be discussed are the HTA co-operation and ADR website enhancements. Health insurance cost Feedback will also be given from the scientific committees.

As part of the ongoing PCWP 10th anniversary celebrations, there will also be a lunch talk on ‘What do you see as the future for the voice of patients at EMA?’ The recording of this will be available at a later date.

Leave a Reply

Your email address will not be published. Required fields are marked *